Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities

Since nivolumab significantly prolongs survival in patients with metastatic melanoma, the number of patients administered nivolumab is increasing, but only 30–40% of patients who received nivolumab monotherapy experienced objective tumor regression. Therefore, enhancing its anti-tumor immune respons...

Full description

Bibliographic Details
Main Authors: Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Takanori Hidaka, Akira Hashimoto, Setsuya Aiba
Format: Article
Language:English
Published: Karger Publishers 2016-10-01
Series:Case Reports in Oncology
Subjects:
Nivolumab
Ipilimumab
Metastatic melanoma
Immune-related adverse event
Immune checkpoint inhibitors
Online Access:http://www.karger.com/Article/FullText/450974

Internet

http://www.karger.com/Article/FullText/450974

Similar Items